Platelet Aggregation in the Diagnosis of Acute Graft Rejection

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Martin

About this trial

The study titled "Platelet Aggregation in the Diagnosis of Acute Graft Rejection" is a pilot observational study evaluating whether alterations in platelet function can serve as non-invasive markers of acute rejection in kidney transplant recipients. Platelet aggregation is assessed using optical aggregometry, flow-cytometric P-selectin (CD62-P) expression, and soluble P-selectin levels before kidney transplantation and at the time of protocol biopsies performed at 3 and 12 months after kidney transplantation. Patients with suspected graft dysfunction undergoing indication biopsy are also included. Platelet activation markers are correlated with histopathological findings, donor-specific antibodies, metabolic parameters, and clinical outcomes. The goal is to determine whether platelet activation profiles can identify acute cellular or antibody-mediated rejection and contribute to the development of a non-invasive diagnostic tool.

Eligibility criteria

Qualifiers

adult patients (≥18 years)

primary kidney transplantation

living / deceased donor kidney transplantation

ability and consent to participate

Disqualifiers

non-adult patients

secondary / tertiary kidney transplantation

antiplatelet therapy

patients unable to provide informed consent

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

60 Participants
are grouped into 2 trial groups

Sponsors and collaborators